INTERNATIONAL PATENT: REGENERON PHARMACEUTICALS, INC. FILES APPLICATION FOR "METHODS OF TREATING ENDOMETRIAL CANCER WITH BISPECIFIC ANTI-MUC16 X ANTI-CD3 ANTIBODIES ALONE OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES"

GENEVA, June 25 -- REGENERON PHARMACEUTICALS, INC. (777 Old Saw Mill River RoadTarrytown, New York 10591) filed a patent application (PCT/US2024/059495) for "METHODS OF TREATING ENDOMETRIAL CANCER WITH BISPECIFIC ANTI-MUC16 X ANTI-CD3 ANTIBODIES ALONE OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES" on Dec 11, 2024. With publication no. WO/2025/128652, the details related to the patent application was published on Jun 19, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ULDRICK JR., Thomas Smith (c/o Regeneron Pharmaceuticals, Inc.777 Old Saw Mill River RoadTarrytown, New York 10591), MILLER, Eli...